Kenneth joseph brown jr m

Kenneth Joseph Brown M.D.
1600 Coit Road
Plano Texas 75075
972-867-0019


Work Experience

Jan. 2010 - present
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER Fellowship in Gastroenterology and Hepatology UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
Education
1994 - 1998
Blair Nebraska B.A. Spanish & Biology
Certification
2004 - 2014
Honors and Awards

2009
Voted as "D Magazine" top Gastroenterologists 2009 Voted as "D Magazine" top Gastroenterologists 2008 Co-Chair Texas Society of Gastrointestinal Endoscopy Meeting Chairman of Gastroenterology section TexMed 2005 Award of Excellence in Outpatient Clinical Care John A Hartford Award for Excellence in Clinical Geriatrics Award of Excellence in Outpatient Clinical Care Selected as Representative for Residency Selection Committee Chosen as Ambassador to Hospital Italiano in Argentina to establish exchange program between UNMC and Hospital Italiano
Research/Presentations

Principal Investigator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled,
Multicenter Study To Assess The Efficacy And Safety Of Budesonide Foam (2mg/25mL
BID For 2 Weeks, Followed By 2mg/25mL QD For 4 Weeks) Versus Placebo In
Subjects With Active Mild To Moderate Ulcerative Proctitis (UP) Or Proctosigmoiditis
(UPS). Ongoing
Principal Investigator, A Randomized, Double-Blind, Multi-Center, 12 Month Extension
Study To Evaluate The Safety and Efficacy of Daily Budesonide MMXTM 6 mg Versus
Placebo In The Maintenance of Remission In Subjects With Ulcerative Colitis. Ongoing
Principal Investigator, Efficacy and Safety of New Oral Budesonide MMX 6mg and 9mg
Extended Release Tablet Formulations in Patients with Mild or Moderate, Active
Ulcerative Colitis. A Multicentre, Randomized, Double Blind, Double Dummy,
Comparative Study Versus Placebo, with An Additional Reference Arm Evaluating
Asacol 2400 mg.
Principal Investigator, A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,
Dose-Ranging Study of COLAL-PRED® in the Treatment of Patients with Moderate to
Severe Ulcerative Colitis.
Principal Investigator, A Phase 3, Randomized, Double-Blind, Placebo-Controlled,
Multicenter Study to Assess The Efficacy and Safety of Rifaximin 550 mg TID In The
Treatment of Subjects With Non-Constipation Irritable Bowel Syndrome.
Sub-Investigator, A Multi-Center, Investigator-Blinded, Randomized, 12 Month Parallel-
Group, Non-Inferiority Study to Compare the Efficacy of 1.6 to 2.4 Asacol Therapy QD
Versus Divided Dose (BID) In the Maintenance of Remission of Ulcerative Colitis.
"The Effect of Pioglitazone in Patients Diagnosed with NASH, and Insulin Resistance: A
Double Blind Placebo Controlled Trial" New England Journal of Medicine v 355 Nov
2006
"Safety and Efficacy of Metallic Stents in the Management of Colorectal Obstruction"
Journal of the Society of Laparoscopic Surgeons. 2005 Oct - Dec 9(4) 454-9
"Affect of Zegerid on 4 day Bravo Ph study in Trauma Victim" Poster Presentation Las
Vegas American College of Gastroenterology Meeting
"Understanding the Implications of Polyps" TexMed Presentation 2005
"Underlying Liver Disease in the Pregnant Patient" Grand Rounds University of Texas
Health Science Center 2004.
"Endoscopic Treatment of Gastroesophageal Reflux" Grand Rounds University of Texas
Health Science Center 2002.
"Effect of Inducing Pyrimidine Dimers through UV Irradiation on B.cereus and E.coli"

Professional Affiliations
American Gastroenterological Association
American College of Gastroenterology
American Society for Gastrointestinal Endoscopy
Collin County Medical Society
American Medical Association

Work Experience

2000 - 2001
Staff Physician for Diabetes and Research Center Internal Medicine Consultant Mission Vista Hospital Internal Medicine Consultant NIX Psychiatric Hospital Developed and assisted teaching of Medical Spanish class Medical Interpreter with Methodist Health System

Source: http://northtexasendo.com/assets/uploaded/documents/186/Dr-Brown-CV.pdf